• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2011 年妇科癌症的主要临床研究进展。

Major clinical research advances in gynecologic cancer in 2011.

机构信息

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

出版信息

J Gynecol Oncol. 2012 Jan;23(1):53-64. doi: 10.3802/jgo.2012.23.1.53. Epub 2012 Jan 9.

DOI:10.3802/jgo.2012.23.1.53
PMID:22355468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3280068/
Abstract

The annual review of 2011 comprised 11 themes of major research achievements in gynecologic oncology including breast cancer. A potential paradigm shift in the management of ovarian cancer was reviewed through comprehensive genomic analyses and a tumor-specific new intraoperative fluorescence imaging technique using folate receptor-α targeted agent, which is expected to improve intraoperative staging and more radical cytoreduction. In addition, updates of bevacizumab and poly (ADP-ribose) polymerase inhibitors, risk-reducing salpingo-oophorectomy, and risk evaluation of pelvic mass were discussed. Regarding cervical cancer, this review covered new findings on human papillomavirus vaccines and human papillomavirus tests as well as the current status of clinical trials on locally advanced cervical cancer. The promising role of sentinel lymph node biopsy in the management of early stage endometrial cancer was followed by two notable clinical researches on: exemestane, an aromatase inhibitor, for the prevention of breast cancer and eribulin, a non-taxane microtubule dynamics inhibitor for the treatment of metastatic breast cancer. Lastly, in premenopausal women with breast cancer, the effect of gonadotropin-releasing hormone analogue on the occurrence of chemotherapy-induced early menopause was discussed.

摘要

2011 年的年度综述包括 11 个妇科肿瘤学的主要研究成果主题,包括乳腺癌。通过全面的基因组分析和使用叶酸受体-α靶向剂的肿瘤特异性新术中荧光成像技术,对卵巢癌的管理进行了潜在的范式转变,预计这将改善术中分期和更激进的细胞减灭术。此外,还讨论了贝伐单抗和多聚(ADP-核糖)聚合酶抑制剂、降低风险的输卵管卵巢切除术以及盆腔肿块风险评估的更新。关于宫颈癌,本综述涵盖了人乳头瘤病毒疫苗和人乳头瘤病毒检测的新发现,以及局部晚期宫颈癌临床试验的现状。前哨淋巴结活检在早期子宫内膜癌管理中的有前途的作用之后,跟进了两项关于芳香酶抑制剂依西美坦用于预防乳腺癌和非紫杉类微管动力学抑制剂埃博霉素用于治疗转移性乳腺癌的显著临床研究。最后,在患有乳腺癌的绝经前妇女中,讨论了促性腺激素释放激素类似物对化疗引起的早绝经发生的影响。

相似文献

1
Major clinical research advances in gynecologic cancer in 2011.2011 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2012 Jan;23(1):53-64. doi: 10.3802/jgo.2012.23.1.53. Epub 2012 Jan 9.
2
Major clinical research advances in gynecologic cancer in 2018.2018 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
3
Major clinical research advances in gynecologic cancer in 2012.2012 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2013 Jan;24(1):66-82. doi: 10.3802/jgo.2013.24.1.66. Epub 2013 Jan 8.
4
Major clinical research advances in gynecologic cancer in 2017.2017 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2018 Mar;29(2):e31. doi: 10.3802/jgo.2018.29.e31.
5
Major clinical research advances in gynecologic cancer in 2014.2014年妇科癌症的主要临床研究进展
J Gynecol Oncol. 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156.
6
Major clinical research advances in gynecologic cancer in 2020.2020 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2021 Jul;32(4):e53. doi: 10.3802/jgo.2021.32.e53.
7
Major clinical research advances in gynecologic cancer in 2021.2021 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43.
8
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
9
Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients.手术卵巢抑制用于激素受体阳性的绝经前乳腺癌患者的辅助治疗。
Int J Gynecol Cancer. 2021 Feb;31(2):222-231. doi: 10.1136/ijgc-2020-001966. Epub 2020 Dec 3.
10
Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.绝经前乳腺癌患者行卵巢切除术的手术发现和结局:妇科肿瘤医师协会女性盆腔研究网络的多中心回顾。
J Minim Invasive Gynecol. 2018 Jan;25(1):111-115. doi: 10.1016/j.jmig.2017.08.643. Epub 2017 Aug 15.

引用本文的文献

1
Laparoscopic and Laparotomic Restaging in Patients With Apparent Stage I Epithelial Ovarian Cancer: A Comparison of Surgical and Oncological Outcomes.I期上皮性卵巢癌患者的腹腔镜和开腹再分期:手术及肿瘤学结局比较
Front Oncol. 2022 Jun 20;12:913034. doi: 10.3389/fonc.2022.913034. eCollection 2022.
2
Immunotherapy Advances for Epithelial Ovarian Cancer.上皮性卵巢癌的免疫治疗进展
Cancers (Basel). 2020 Dec 11;12(12):3733. doi: 10.3390/cancers12123733.
3
Robotic single-site staging operation for early-stage endometrial cancer: initial experience at a single institution.早期子宫内膜癌的机器人单孔分期手术:单机构的初步经验
Obstet Gynecol Sci. 2019 May;62(3):149-156. doi: 10.5468/ogs.2019.62.3.149. Epub 2019 Apr 12.
4
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.2016年妇科癌症的主要临床研究进展:十年特刊
J Gynecol Oncol. 2017 May;28(3):e45. doi: 10.3802/jgo.2017.28.e45. Epub 2017 Mar 24.
5
Biosynthesized Platinum Nanoparticles Inhibit the Proliferation of Human Lung-Cancer Cells in vitro and Delay the Growth of a Human Lung-Tumor Xenograft in vivo: -In vitro and in vivo Anticancer Activity of bio-Pt NPs.生物合成的铂纳米颗粒在体外抑制人肺癌细胞的增殖,并在体内延缓人肺肿瘤异种移植瘤的生长:生物铂纳米颗粒的体外和体内抗癌活性
J Pharmacopuncture. 2016 Jun;19(2):114-21. doi: 10.3831/KPI.2016.19.012.
6
Tissue miR-193b as a Novel Biomarker for Patients with Ovarian Cancer.组织微小RNA-193b作为卵巢癌患者的新型生物标志物
Med Sci Monit. 2015 Dec 16;21:3929-34. doi: 10.12659/msm.895407.
7
A molecular understanding of D-homoestrone-induced G2/M cell cycle arrest in HeLa human cervical carcinoma cells.对D-高雌酮诱导人宫颈癌HeLa细胞G2/M期细胞周期阻滞的分子机制理解
J Cell Mol Med. 2015 Oct;19(10):2365-74. doi: 10.1111/jcmm.12587. Epub 2015 Jul 31.
8
L1 cell adhesion molecule expression is associated with pelvic lymph node metastasis and advanced stage in diabetic patients with endometrial cancer: a matched case control study.L1细胞黏附分子表达与糖尿病子宫内膜癌患者盆腔淋巴结转移及晚期相关:一项配对病例对照研究。
J Cancer Prev. 2014 Sep;19(3):231-9. doi: 10.15430/JCP.2014.19.3.231.
9
Ovarian cancer biomarker discovery based on genomic approaches.基于基因组学方法的卵巢癌生物标志物发现
J Cancer Prev. 2013 Dec;18(4):298-312. doi: 10.15430/jcp.2013.18.4.298.
10
Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells.雌激素联合孕激素可降低卵巢癌细胞的细胞增殖,并通过微小RNA let-7a和miR-34b抑制Bcl-2的表达。
Clin Transl Oncol. 2014 Oct;16(10):898-905. doi: 10.1007/s12094-014-1166-x. Epub 2014 Mar 19.

本文引用的文献

1
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.尼拉帕尼(BSI-201)联合吉西他滨和顺铂治疗复发性卵巢癌的 II 期临床试验。
Oncologist. 2023 Mar 17;28(3):252-257. doi: 10.1093/oncolo/oyac275.
2
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.遗传/家族性高风险评估:乳腺癌、卵巢癌和胰腺癌,第 2.2021 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
3
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.对妇科肿瘤学组研究 0218 的独立放射学评估,这是一项贝伐珠单抗用于晚期上皮性卵巢癌、原发性腹膜癌或输卵管癌初始治疗的 III 期临床试验。
Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.
4
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.OCEANS:一项在铂敏感复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌患者中进行的化疗联合或不联合贝伐珠单抗的随机、双盲、安慰剂对照 III 期试验。
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
5
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.HPV-16/18 AS04 佐剂疫苗对 3 级或更高级别宫颈上皮内瘤变的总体疗效:随机、双盲 PATRICIA 试验的 4 年研究结束时分析。
Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8.
6
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.HPV-16/18 AS04 佐剂疫苗对非疫苗型致癌 HPV 引起的宫颈感染和癌前病变的交叉保护效力:随机、双盲 PATRICIA 试验的 4 年研究结束时分析。
Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8.
7
Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.用于宫颈癌预防的人乳头瘤病毒检测的阴道标本自我采集(MARCH):一项基于社区的随机对照试验。
Lancet. 2011 Nov 26;378(9806):1868-73. doi: 10.1016/S0140-6736(11)61522-5. Epub 2011 Nov 1.
8
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.血清人附睾蛋白 4 和卵巢恶性肿瘤算法作为上皮性卵巢癌管理的新的诊断和预后工具。
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.
9
Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening.50 岁及以上未参加巴氏涂片筛查的女性的阴道液自我采样和高危型人乳头瘤病毒检测。
BJOG. 2012 Jan;119(2):245-8. doi: 10.1111/j.1471-0528.2011.03147.x. Epub 2011 Oct 21.
10
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results.叶酸受体-α靶向的卵巢癌术中肿瘤特异性荧光成像:首例人体研究结果。
Nat Med. 2011 Sep 18;17(10):1315-9. doi: 10.1038/nm.2472.